Hostname: page-component-586b7cd67f-rdxmf Total loading time: 0 Render date: 2024-11-25T19:04:33.952Z Has data issue: false hasContentIssue false

Cost-effectiveness of clozapine

Published online by Cambridge University Press:  02 January 2018

R. W. Kerwin
Affiliation:
Section of Clinical Neuropharmacology, Institute of Psychiatry, London SE5 8AF
K. J. Aitchison
Affiliation:
Section of Clinical Neuropharmacology, Institute of Psychiatry, London SE5 8AF
Rights & Permissions [Opens in a new window]

Abstract

Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Columns
Copyright
Copyright © 1997 The Royal College of Psychiatrists 

References

Aitchison, K. & Kerwin, R. W. (1997) Cost-effectiveness of clozapine. British Journal of Psychiatry, 171, 125130.CrossRefGoogle ScholarPubMed
Baldessarini, R. J. & Frankenburg, F. R. (1991) Clozapine. A novel antipsychotic agent. New England Journal of Medicine, 324, 746754.Google ScholarPubMed
Robert, G. & Kennedy, P. (1997) Establishing cost-effectiveness of atypical neuroleptics. British Journal of Psychiatry, 171, 103104.CrossRefGoogle ScholarPubMed
Umbricht, D. S. G., Lieberman, J. A. & Kane, J. M. (1995) The clinical efficacy of clozapine in the treatment of schizophrenia. Reviews in Contemporary Pharmacotherapy, 6, 165186.Google Scholar
Wahlbeck, K., Cheine, M., Essali, M. A., et al (1997) Clozapine for schizophrenia. Clozapine versus ‘typical’ neuroleptic medication for schizophrenia. In Schizophrenia Module (eds Adams, C. E., Duggan, L., De Jesus, M. J., et al). The Cochrane Database of Systematic Reviews (available in the Cochrane Library). London: BMJ Publishing.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.